Record First Quarter Sees Pharmaceutical Software and Services Revenues Jump 21%, Consolidated Earnings Up 38% from 1QFY09
Paul Volcker: Think More Boldly
In December 2009, The Wall Street Journal sponsored its second Future of Finance Initiative (links to a dead page) to provide a forum for 80 of the world’s top financiers to brainstorm suggestions for reforming the financial system in the wake of the 2008 implosion of the global economy.
Development of a Physiologically Based Pharmacokinetic (PBPK) Model for Predicting Deposition and Disposition follo · g Inhaled and Intranasal Administration
The selection of a biologically active molecule as a successful inhaled therapeutic agent depends on its pharmacokinetic and safety properties...
Simulations Plus Appoints John DiBella, M.S., Manager, Marketing and Sales
New Leadership Brings Strength in Science and Engineering
Simulations Plus Appoints Robert D. Clark, PH. D., Director of Life Sciences
Dr. Clark to Join Team in January
Simulations Plus Launches Abbreviate!™ for the iPhone™
New Software Speeds Up Typing on the PopularApple® iPhoneTM and iPod Touch®
Modeling Drug Disposition of Timolol in Ocular Tissues of Rabbit following Topical Eye Drops
Recently, we reported the successful application of a novel mathematical model describing drug disposition in eye compartments to simulate disposition of clonidine after topical (eye drop) administration.
David Foster Wallace
I have become addicted to David Foster Wallace’s nonfiction essays, several of which were published in A Supposedly Fun Thing I’ll Never Do Again.*
Prediction of pharmacokinetic profile of valsartan in human based on in vitro uptake transport data
The aim of this study was to evaluate a strategy based on a physiologically based pharmacokinetic (PBPK) model for the prediction of PK profiles in human using in vitro...
Simulations Plus Reports FY2009 Financial Results
Sales up 2% to $9.143 Million, Cash up 26.9%, Earnings $0.08 Per Fully Diluted Share
Simulations Plus Sets Date for Fiscal Year 2009 Earnings Release and Conference Call
Conference Call to Be on Monday, November 30, at 4:15 PM EST
Simulations Plus Releases GastroPlus Version 6.1
Flagship Product Features New Routes of Administration & Numerous User Conveniences
Optimizing the Performance of In Silico ADMET General Models According to Local Requirements: MARS Approach. Solubility Estimations As Case Study
The quality of in vitro data used to build in silico absorption, distribution, metabolism, and toxicity (ADMET) models is, in many cases, inconsistent.
An Uncommon Vignette?
Part 1
The CEO of a pharmaceutical company, tired of late-stage development failures and FDA questioning regarding dose selection, decides to act on the promise of pharmacometrics. “Fix it,” he says to the head of clinical pharmacology, “I don’t care what it takes!” The clinical pharmacologist agrees to take on the challenge and asks for a data programmer and pharmacometrician. Seizing on an opportunity to spearhead an upcoming “end of phase 2” meeting with the FDA, the pharmacologist quickly sketches out his strategy for the modeling activities required for dose selection and justification. He then instructs his programmer to assemble the required dataset using the data from several phase 1 studies and a recently completed phase 2 study. A week later he discovers that the modeling has not begun because the dataset is still not ready. “What is taking so long?” he wonders.
Modeling Fluconazole – a Case with Concentration-Dependent Liver:Plasma Partition Coefficient
Fluconazole is an antifungal agent widely used in the clinical setting for the treatment of candidiasis and meningitis. It undergoes minimal metabolism and is excreted renally.
PBPK Modeling of Fluoxetine and its Metabolite Norfluoxetine: Prediction of the Extent of Their Involvement in Drug Interactions
The aim of our study was to simulate the human pharmacokinetics of fluoxetine and its major metabolite, norfluoxetine, and predict the magnitude of their drug-drug interactions (DDIs) using physiologically…
In Silico Prediction of Aqueous Solubility: The Solubility Challenge
The dissolution of a chemical into water is a process fundamental to both chemistry and biology. The persistence of a chemical within the environment and the effects of a chemical...
A Pharmacokinetic Simulation-Based Comparison Of Varying Adherence Rates For Paliperidone ER And Risperidone In Patients With Schizophrenia
Medication adherence is important to successful management of • patients with schizophrenia and related psychotic disorders; patient nonadherence is documented in numerous studies (e.g., 30%-35%…
Square Pegs in Round Holes?
A crusading scientist identifies a potential public health threat and uses the internet to get access to a cache of data from several studies. After a quick analysis of the pooled data, he reports a previously unrecognized adverse effect of a widely used drug. Patients and physicians become alarmed, and the drug is pulled from the market. Sound like the plot of a new medical thriller? In fact, a similar scenario has hit the headlines several times in the last 10 years. Each time, controversy about the validity of the analysis and conclusions was loud and lasting.